NCT00269880View on ClinicalTrials.gov

A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,792

Participants

Timeline

Start Date

February 28, 1995

Primary Completion Date

December 31, 1995

Study Completion Date

December 31, 1995

Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Interventions
DRUG

Placebo

Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.

DRUG

Heparin

Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.

DRUG

Abciximab

Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY